Literature DB >> 22190506

Developmental delays in children with neurofibromatosis type 1.

Elizabeth A Soucy1, Feng Gao, David H Gutmann, Courtney M Dunn.   

Abstract

It is well documented that children with neurofibromatosis type 1 are at high risk for a variety of cognitive and learning deficits. The current study investigated the use of a developmental screening tool, the Parents' Evaluation of Developmental Status: Developmental Milestones, as an accurate, reliable, and efficient indicator of developmental delays. Sixty-eight percent of children with neurofibromatosis type 1 were found to have a developmental delay in at least 1 of the 8 areas tested by the Parents' Evaluation of Developmental Status: Developmental Milestones. Significant developmental abnormalities were found in the areas of fine motor (35%), gross motor (52%), and math/premath (31%). A positive association was found between the presence of a previously diagnosed optic glioma and math/premath delays (χ(2) = 0.0022) and between male sex and fine motor delays (χ(2) = 0.0325). The Parents' Evaluation of Developmental Status: Developmental Milestones assessment demonstrates the high presence of developmental delays in children with neurofibromatosis type 1 and the need for aggressive and early screening.

Entities:  

Mesh:

Year:  2011        PMID: 22190506     DOI: 10.1177/0883073811423974

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  11 in total

1.  Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.

Authors:  Sandra P Toelle; Andrea Poretti; Peter Weber; Tatjana Seute; Jacoline E C Bromberg; Ianina Scheer; Eugen Boltshauser
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

Review 2.  Neurofibromatosis type 1: modeling CNS dysfunction.

Authors:  David H Gutmann; Luis F Parada; Alcino J Silva; Nancy Ratner
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

3.  Sexual Self-Esteem and Psychological Burden of Adults With Neurofibromatosis Type 1.

Authors:  Anna Leidger; Marie Vosschulte; Timo O Nieder; Victor-Felix Mautner
Journal:  Front Psychol       Date:  2022-06-09

Review 4.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

5.  Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.

Authors:  Corina Anastasaki; David H Gutmann
Journal:  Hum Mol Genet       Date:  2014-07-28       Impact factor: 6.150

6.  Cognitive and psychosocial phenotype of young children with neurofibromatosis-1.

Authors:  Bonita P Klein-Tasman; Kelly M Janke; Wen Luo; Christy L Casnar; Scott J Hunter; James Tonsgard; Pamela Trapane; Faye van der Fluit; Lorri A Kais
Journal:  J Int Neuropsychol Soc       Date:  2013-11-15       Impact factor: 2.892

7.  Motor problems in children with neurofibromatosis type 1.

Authors:  André B Rietman; Rianne Oostenbrink; Sanne Bongers; Eddy Gaukema; Sandra van Abeelen; Jos G Hendriksen; Caspar W N Looman; Pieter F A de Nijs; Marie-Claire de Wit
Journal:  J Neurodev Disord       Date:  2017-05-19       Impact factor: 4.025

Review 8.  Atypical NF1 Microdeletions: Challenges and Opportunities for Genotype/Phenotype Correlations in Patients with Large NF1 Deletions.

Authors:  Hildegard Kehrer-Sawatzki; Ute Wahlländer; David N Cooper; Victor-Felix Mautner
Journal:  Genes (Basel)       Date:  2021-10-19       Impact factor: 4.096

9.  Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1.

Authors:  Giovanni Corsello; Vincenzo Antona; Gregorio Serra; Federico Zara; Clara Giambrone; Luca Lagalla; Maria Piccione; Ettore Piro
Journal:  Ital J Pediatr       Date:  2018-04-04       Impact factor: 2.638

10.  Clinical characterization of children and adolescents with NF1 microdeletions.

Authors:  Hildegard Kehrer-Sawatzki; Lan Kluwe; Johannes Salamon; Lennart Well; Said Farschtschi; Thorsten Rosenbaum; Victor-Felix Mautner
Journal:  Childs Nerv Syst       Date:  2020-06-12       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.